Genmab A/S is a Denmark-based biotechnology company. The Company was founded as a European spin-off of American Biotech company Medarex in February 1999. The firm is engaged in the development of differentiated human antibody therapeutics for the treatment of cancer, as well as other medical conditions, such as Rheumatoid Arthritis and Relapsing Remitting Multiple Sclerosis. Its product pipeline includes a number of research and development projects in various phases of development, such as Ofatumumab for the treatment of, among others, Waldenstroms Macroglobulinemia and Chronic lymphocytic leukemia; Daratumumab for the treatment of Multiple myeloma RG1512 for the treatment of Saphenous vein graft disease and Acute coronary syndrome, and HuMax-TF-ADC for the treatment of solid cancers, among others. The Company develops its projects under worldwide co-development and commercialization agreements with GlaxoSmithKline, Roche, H. Lundbeck A/S and Seattle Genetics. As of December 31, 2011, the Company had three wholly owned subsidiaries.
